Breast Cancer Caregiver Survey: Women Being Treated with Herceptin-Perjeta Combination Therapy

The pan-Canadian Oncology Drug Review (pCODR) makes recommendations about whether the provincial health plans should pay for new cancer drugs. pCODR will soon be reviewing the use of Herceptin-Perjeta combination therapy to treat HER2-positive early breast cancer.
Rethink Breast Cancer will be making a submission to ensure that patient voices are represented and considered during the review process. We would also like to speak with family friends about their experience caring for women being treated with Herceptin-Perjeta combination therapy.